Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

BIOABullishCorporate Developmentsnews

High materiality8/10

BioAge advances BGE-102 with QUELL-CV topline data expected in 2H2026

Aug 5, 2026, 4:53 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive topline data expectations for QUELL-CV and expanding DME program could drive sentiment and valuation, especially given strong Phase 1 NLRP3 data and significant cash runway. Historically, similar near-term Phase 2 readouts in inflammasome inhibitors have spurred upside moves when data align with expectations.

AI summary

What happened, with direct paths to the underlying reporting

BioAge outlined Q2 2026 progress for BGE-102, including a first participant in QUELL-CV with topline readouts due in 2H2026 and a mid-2026 start for QUELL-DME with data by mid-2027. The company emphasized a robust cash position and ongoing strategic collaborations with Novartis and Lilly ExploR&D, which could de-risk multiple indications and broaden the pipeline.

First participant dosed in QUELL-CV; topline data expected in H2 2026.
QUELL-DME Phase 1b/2a planned mid-2026; data mid-2027.
Phase 1 data: BGE-102 inhibits NLRP3; IL-1β suppression up to 98%.
R&D Day highlighted NLRP3 strategy; BioAge cash runway to 2029.
Novartis collaboration persists; Lilly ExploR&D antibodies advancing.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

BioAge advances BGE-102 with QUELL-CV topline data expected in 2H2026

ZEUS data questions hsCRP–MACE link; BioAge valuation at risk

BioAge Labs Reports Positive Phase 1 Data, Fuels Bullish Sentiment